Dan Hess (@dhess280) 's Twitter Profile
Dan Hess

@dhess280

Heme/Onc Fellow at Duke by way of @universityofga, @UVaMSTP @lab_owens, @uabimres. Views are mine

ID: 1466768234359701505

calendar_today03-12-2021 13:56:22

20 Tweet

39 Takipçi

105 Takip Edilen

Mushtaq Bilal, PhD (@mushtaqbilalphd) 's Twitter Profile Photo

An Interview with the Nature editor who rejected the paper that won the Nobel Prize In mid-2000s, Katalin Karikó submitted one of her papers to Nature, the prestigious academic journal. Nature desk rejected her paper saying that it did not offer any original insights and that

Denis Wirtz (@deniswirtz) 's Twitter Profile Photo

With our highly modular VELOCIREPTORS, we can generate >30,000 different types of self-propelled CAR T cells designed to infiltrate solid tumors. We test 5 in mouse models of pancreatic/ovarian/lung cancer, 3 cancers with poor survival rates. Here: biorxiv.org/content/10.110…

With our highly modular VELOCIREPTORS, we can generate >30,000 different types of self-propelled CAR T cells designed to infiltrate solid tumors.

We test 5 in mouse models of pancreatic/ovarian/lung cancer, 3 cancers with poor survival rates.

Here: biorxiv.org/content/10.110…
The Clinical Problem Solvers (@cpsolvers) 's Twitter Profile Photo

#MedTwitter Join us for a ~blast~ with this Hematology VMR! We will be joined by the infamous Papa Heme @AaronGoodman33 discussing a hematology case with Heme/Onc Fellow extraordinaire Gabriel Aleixo! We can’t wait to see you tomorrow, Feb. 19 at 9pm EST! bit.ly/31LWIKg

#MedTwitter Join us for a ~blast~ with this Hematology VMR!

We will be joined by the infamous Papa Heme @AaronGoodman33 discussing a hematology case with Heme/Onc Fellow extraordinaire <a href="/chefaleixomd/">Gabriel Aleixo</a>!

We can’t wait to see you tomorrow, Feb. 19 at 9pm EST! bit.ly/31LWIKg
Vinay Prasad MD MPH (@vprasadmdmph) 's Twitter Profile Photo

Less than half of cancer drugs approved based on a surrogate endpoint are ever found to improve survival in their entire lifecycle. ncbi.nlm.nih.gov/pmc/articles/P…

Less than half of cancer drugs approved based on a surrogate endpoint are ever found to improve survival in their entire lifecycle.

ncbi.nlm.nih.gov/pmc/articles/P…
Ramy Sedhom, MD, FASCO (@ramsedhom) 's Twitter Profile Photo

A positive trial for cancer cachexia - a very distressing symptom to patients and caregivers! Congrats to my bud @MDRoeland for being an NEJM author

Duke Hematologic Malignancies & Cellular Therapy (@dukehmct) 's Twitter Profile Photo

#myeloMATCH clinical trials are now open at Duke Cancer, using advanced biomarker testing to optimize therapy for patients with #AML & #MDS. An National Cancer Institute precision medicine endeavor led by Duke's own Dr. #HarryErba and Dr. Richard Little of the NCI. swog.org/myelomatch-ove…

#myeloMATCH clinical trials are now open at <a href="/DukeCancer/">Duke Cancer</a>, using advanced biomarker testing to optimize therapy for patients with #AML &amp; #MDS. An <a href="/theNCI/">National Cancer Institute</a> precision medicine endeavor led by Duke's own Dr. #HarryErba and Dr. Richard Little of the NCI.

swog.org/myelomatch-ove…
Anish Koka, MD (@anish_koka) 's Twitter Profile Photo

I really don’t think people realize how incredibly hard and complex real cancer is to treat. Oncologists would happily treat their dying patients with this. It just isn’t true that there’s a simple off the shelf generic that magically cures all cancers.

Vinay Prasad MD MPH (@vprasadmdmph) 's Twitter Profile Photo

A commenter writes, "This makes my blood boil with anger." Learn why he is right about a NIH funded study published in NEJM sensible-med.com/p/a-new-costly…

Nature Cancer (@naturecancer) 's Twitter Profile Photo

🔔Take a look at this article now published Nature Cancer ! 'Tumor antigens preferentially derive from unmutated genomic sequences in #melanoma and non-small cell #lungcancer' ✏️By Pierre Thibault, Claude Perreault and colleagues 🔗nature.com/articles/s4301…